The patent claims, include self-centering fluid bag hangers and density compensation mechanisms for enhanced accuracy in fluid management. Ease of use is increased with self-sealing access ports for easy configuration of various dialysis modes, streamlining the treatment process. Additionally, reliability is boosted by a temperatureadjusting auto-clamp that ensures secure seals, reducing the risk of leaks and enhancing overall system dependability. About the Aquadex SmartFlow® System MINNEAPOLIS, June 25, 2 ...

This program aims to pilot Aquadex® ultrafiltration therapy for adult patients suffering from congestive heart failure and related conditions in select U.S. markets. Today, DaVita serves as a leading provider of kidney care services, including acute and outpatient dialysis care for patients in-center and at home. The extension of the pilot will allow additional time to evaluate ultrafiltration therapy using the Aquadex SmartFlow system with high-need patients in the hospital. Nuwellis, Inc. (Nasdaq: NUWE) i ...

MINNEAPOLIS, May 14, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced the launch of a new pediatric ultrafiltration program utilizing Nuwellis' Aquadex SmartFlow System® at one of the largest health integrated delivery networks (IDN) in Florida. This program marks an expansion by this network to offer ultrafiltration to its pediatric patients, in addition to its current heart failure and criti ...

MINNEAPOLIS, May 09, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced a new purchase agreement with one of the top 25 largest integrated delivery networks (IDN) in the U.S. Nuwellis has a successful history of collaborating with individual member hospitals within the IDN on Aquadex utilization. This new network-wide agreement signifies a broader commitment to providing advanced ultrafiltration ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission file number 001-35312 NUWELLIS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware No. 68-0533453 (State or Other J ...

Exhibit 99.1 Nuwellis, Inc. Announces First Quarter 2024 Financial Results Minneapolis, MN, May 7, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today reported financial results for the first quarter ended March 31, 2024. Highlights: "We are pleased to see firm utilization, led by Pediatrics and in Critical Care, driving first-quarter revenue," said Nestor Jaramillo, President and CEO of Nuwellis. "Increa ...

11 | FOR INVESTOR PURPOSES ONLY: NOT FOR PRODUCT PROMOTION ©2024 Nuwellis, Inc. 3 Hematocrit sensor monitors preset hematocrit limits 5 Filtered blood returns to the patient via the infusion line Ultrafiltration pump can pull 0-500 ml of fluid per hour 15 | FOR INVESTOR PURPOSES ONLY: NOT FOR PRODUCT PROMOTION ©2024 Nuwellis, Inc. AQ LD At a Recent Late Breaking Clinical Trials, Significant Reduction in HF Events and HF Hospitalization resent at THT 2024 in early March, a re-appraisal of a 224-patients cont ...

MINNEAPOLIS, April 30, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE) ("Nuwellis" or the "Company"), a medical technology company focused on transforming the lives of people with fluid overload, today announced the closing of its previously announced public offering of 11,250,000 shares of its common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to an aggregate of 16,875,000 shares of its common stock at a combined public offering price of $0.24 per share (or pre-funded w ...

MINNEAPOLIS, April 30, 2024 (GLOBE NEWSWIRE) --  Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced that it will release financial results for the first quarter of 2024 on Tuesday, May 7, 2024. Nuwellis will host a conference call and webcast at 9:00 AM ET to discuss its financial results and provide a general business update. To access the live webcast, please visit the Investors page of the Nuwellis website at https:/ ...

MINNEAPOLIS, April 30, 2024 (GLOBE NEWSWIRE) --  Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced that it will release financial results for the first quarter of 2024 on Tuesday, May 7, 2024. Nuwellis will host a conference call and webcast at 9:00 AM ET to discuss its financial results and provide a general business update. To access the live webcast, please visit the Investors page of the Nuwellis website at https: ...